Salivary Gland Cancer Treatment Market Size & Forecast 2035
The global salivary gland cancer treatment market was valued at USD 320 million in 2025 and is projected to reach USD 526.2 million by 2035, growing at a 5.1% CAGR during 2026-2035.
Salivary gland cancer is not one uniform commercial indication. It consists of more than 20 histologic subtypes with different natural histories and molecular drivers. Mucoepidermoid carcinoma is the largest diagnosed category, while adenoid cystic carcinoma attracts the greatest concentration of late-stage drug development because recurrent or metastatic disease lacks an established systemic standard. Salivary duct carcinoma creates a smaller but molecularly actionable segment through androgen-receptor and HER2 expression.
The treatment model is changing from histology-only decisions to histology-plus-biomarker selection. HER2, androgen receptor, NTRK fusion, B7-H4, MYB pathway activity, NOTCH alterations, EGFR and TROP2 can define narrower treatment groups. The commercial consequence is a portfolio of rare molecular submarkets rather than one high-volume drug category. Trial networks, central pathology, genomic testing and multinational recruitment are therefore essential parts of market access.
Key Highlights
- 2025 market value: USD 320 million
- 2026 market value: USD 336.3 million
- 2035 forecast: USD 526.2 million
- Forecast CAGR: 5.1% during 2026-2035
- Largest 2025 treatment segment: Surgery, 35% or USD 112 million
- Largest 2025 histology: Mucoepidermoid carcinoma, 37% or USD 118.4 million
- Largest 2025 end user: Hospitals and comprehensive cancer centers, 72% or USD 230.4 million
- Largest 2025 region: North America, 41% or USD 131.2 million
- Highest-value pipeline focus: Recurrent or metastatic adenoid cystic carcinoma
Market Dynamics
Rare histologies are becoming separate development markets
Adenoid cystic carcinoma, mucoepidermoid carcinoma, salivary duct carcinoma and secretory carcinoma differ in growth rate, metastatic behavior and therapeutic targets. Combining them in one trial can obscure efficacy because stable disease in slow-growing ACC is not equivalent to tumor control in an aggressive salivary duct carcinoma. Regulators and developers are moving toward histology-defined cohorts with molecular enrichment, creating smaller but more interpretable addressable populations.
ACC is moving closer to registration-directed development
Three October 2026 events sharpened the competitive landscape. Servier dosed the first patients in the pivotal Phase II EMBLEM-1 cohort for the B7-H4 antibody-drug conjugate emiltatug ledadotin. Rgenta aligned with the FDA on a Phase III design for the MYB-targeting oral molecule RGT-61159. Avacta reported updated faridoxorubicin data in a defined salivary gland cancer subset. These programs use different mechanisms and endpoints, which could create the first differentiated systemic-treatment choices for advanced disease if pivotal evidence confirms benefit.
Surgery and radiation retain the largest current treatment role
Localized disease is primarily managed through tumor resection, with neck dissection and reconstruction selected according to site, stage and nodal involvement. Postoperative radiation is used for adverse features such as positive margins, perineural invasion, high-grade disease and advanced stage. Drug development will expand the systemic-therapy pool, but it will not displace surgery in resectable localized disease during the forecast period.
Biomarker testing changes the value of small patient groups
HER2-positive and androgen-receptor-positive salivary duct carcinoma can be approached with targeted strategies used in other tumor types, while NTRK fusion-positive secretory carcinoma may qualify for tumor-agnostic TRK inhibitors. The absolute number of patients is low, but biomarker selection raises the probability of response and supports premium targeted treatment. Routine comprehensive profiling is therefore commercially important despite the limited incidence.
Trial recruitment is the central operating constraint
The U.S. incidence rate is about 1.3 cases per 100,000 people annually, and each histologic or molecular subset is smaller still. A single center cannot recruit a registration study efficiently. Sponsors need referral networks, central pathology review, international sites and patient-advocacy engagement. Slow enrollment can extend development timelines more than formulation or manufacturing work.
Historical controls require cautious use
Single-arm studies are common because randomization is difficult in rare cancers. However, ACC can progress slowly, and progression-free survival varies by histology and prior treatment. Apparent improvement against historical benchmarks must be confirmed with prospectively defined populations and consistent assessment schedules. This is especially important when reported datasets exclude rare histologies or heavily pretreated patients.
Market Segmentation
By Treatment
Surgery held 35% of 2025 revenue, equal to USD 112 million. Parotidectomy, submandibular-gland excision, neck dissection, skull-base procedures and reconstruction form the core of localized treatment. Revenue reflects procedure-related treatment activity within the defined market, not total hospital charges.
Radiation therapy represented 24%, or USD 76.8 million. Postoperative external-beam radiation is important for high-risk disease, while definitive radiation may be used when surgery is not feasible. Proton and other precision techniques are relevant where tumors track along nerves or lie near critical structures.
Chemotherapy accounted for 17%, or USD 54.4 million. Cisplatin, carboplatin, taxanes, anthracyclines and combination regimens are used in selected recurrent or metastatic cases, but durable responses are uncommon. Faridoxorubicin seeks to improve doxorubicin delivery by releasing the active drug in fibroblast-activation-protein-rich tumor tissue.
Targeted therapy generated 14%, or USD 44.8 million. The segment includes eligible HER2-, androgen-receptor-, NTRK- and other molecularly selected treatment activity. Its share is expected to rise as testing becomes routine and ACC-directed agents progress.
Immunotherapy represented 5%, or USD 16 million. Checkpoint inhibitors are used selectively and studied in trials, but activity varies by histology and immune phenotype. Low response rates in unselected disease limit broad use.
By Histology
Mucoepidermoid carcinoma was the largest segment at 37% in 2025, equal to USD 118.4 million. Low-grade tumors are often treated successfully with surgery, while high-grade or metastatic disease requires multimodal management. Grade and MAML2 fusion status can inform classification and prognosis.
Adenoid cystic carcinoma accounted for 28%, or USD 89.6 million. ACC is characterized by perineural invasion, late recurrence and distant metastasis, often to the lungs. Its large value share relative to incidence reflects repeated imaging, radiation, prolonged follow-up and an active investigational pipeline.
Acinic cell carcinoma represented 11%, or USD 35.2 million. Surgery dominates localized care, but high-grade transformation can produce more aggressive behavior and systemic-treatment demand.
Salivary duct carcinoma held 9%, or USD 28.8 million. This histology is commercially important because HER2 amplification or overexpression and androgen-receptor positivity can support targeted treatment strategies.
Secretory carcinoma accounted for 5%, or USD 16 million. Many cases harbor ETV6-NTRK3 fusions, creating eligibility for tumor-agnostic TRK inhibitors in advanced disease.
By End User
Hospitals and comprehensive cancer centers controlled 72% of 2025 revenue, or USD 230.4 million, because surgery, radiation, infusion therapy and multidisciplinary pathology are concentrated in tertiary institutions. Specialty oncology and head-and-neck clinics held 18%, or USD 57.6 million, primarily through systemic therapy, surveillance and follow-up. Ambulatory surgical centers represented 6%, or USD 19.2 million, while research institutions and other settings accounted for 4%, or USD 12.8 million.
By Route of Systemic Administration
Intravenous treatment accounted for 71% of systemic-therapy value in 2025, reflecting chemotherapy, antibody-drug conjugates and monoclonal antibodies. Oral therapy held 21%, supported by tyrosine-kinase, hormonal and investigational RNA-targeting agents. Other routes represented 8%. The oral share could rise if RGT-61159 or other targeted small molecules reach the market.
Regional and Country-Level Analysis
North America
North America represented 41% of the 2025 market, equal to USD 131.2 million. The United States held 37% of global revenue, or USD 118.4 million, supported by specialized head-and-neck centers, genomic profiling, clinical-trial infrastructure and higher oncology treatment expenditure. Canada contributed the remaining regional share. The U.S. market is the principal regulatory battleground: Servier, Avacta and Rgenta each reported FDA-related pivotal progress in 2026.
Europe
Europe accounted for 28%, or USD 89.6 million. Germany, France, the United Kingdom, Italy and Spain contribute specialist surgical and radiation capacity and multinational trial sites. France-based Servier has a pivotal ACC program, while UK-based Avacta is developing faridoxorubicin. Fragmented referral pathways and country-specific reimbursement can slow access to rare-cancer specialists and molecular testing.
Asia-Pacific
Asia-Pacific held 24%, or USD 76.8 million, and is expected to grow faster than the mature regions. Japan represented 9% of global value, or USD 28.8 million. Japan’s 2021 approval of trastuzumab for unresectable advanced or recurrent HER2-positive salivary gland cancer created a defined biomarker-led treatment segment. China held 7%, or USD 22.4 million, with growing ADC, radiotherapy and biomarker-driven research. South Korea, Australia and India collectively accounted for 6%, or USD 19.2 million, while the rest of the region held 2%, or USD 6.4 million.
Competitive Landscape
The market is shifting from repurposed cytotoxic and head-and-neck regimens toward histology-specific pipelines. Relevant participants include Servier, Avacta Therapeutics, Rgenta Therapeutics, Roche/Chugai, Merck & Co., Bristol Myers Squibb, Pfizer, Novartis, Bayer, Eli Lilly, Gilead Sciences and TRK-inhibitor developers. The competitive variables are biomarker definition, histology-specific response, durability, tolerability, trial recruitment and regulatory acceptance of single-arm or rare-disease evidence.
Avacta Therapeutics
Avacta is developing faridoxorubicin, also known as AVA6000, a fibroblast-activation-protein-enabled form of doxorubicin designed to release active drug in the tumor microenvironment. In June 2026 the company reported FDA agreement on a single pivotal study using progression-free survival as the primary endpoint for potential full approval in selected first- and second-line salivary gland cancer populations. In October it reported a median PFS of 11.4 months in a defined 32-patient subset treated at 310 mg/m² or above. The result is an early clinical signal from a selected analysis, not proof of approval-level benefit.
Servier
Servier is developing emiltatug ledadotin, a B7-H4-directed antibody-drug conjugate with an auristatin-F payload. The FDA granted Breakthrough Therapy designation in May 2026 for locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation. In October, Servier dosed the first patients in the pivotal Phase II EMBLEM-1 cohort, with objective response rate as the primary endpoint. The program targets an aggressive ACC subset where no FDA-approved systemic therapy exists.
Rgenta Therapeutics
Rgenta develops oral small molecules that modulate RNA and RNA regulation. RGT-61159 targets the MYB oncogenic pathway, which is central to ACC biology. In October 2026 the company reported FDA alignment on a Phase III design and plans to begin pivotal development in early 2027. Preliminary data cited a disease-control rate of 84.6% among 39 patients treated at or below the recommended Phase II dose, including three partial responses. The registration case will need to distinguish pharmacologic control from ACC’s naturally indolent behavior in some patients.
Roche and Chugai Pharmaceutical
Roche and Chugai supply HER2-targeted treatment through trastuzumab. Japan approved trastuzumab for advanced or recurrent HER2-positive salivary gland cancer not amenable to curative resection in 2021. The product demonstrates how a biomarker-defined subset can support a specific national indication despite low patient numbers. Commercial relevance is concentrated in salivary duct carcinoma and other HER2-positive tumors identified through validated testing.
Recent Developments
- October 26, 2026 - Avacta: Updated Phase I data reported median PFS of 11.4 months in a defined 32-patient salivary gland cancer subset receiving faridoxorubicin at 310 mg/m² or above; the comparison with historical benchmarks is non-randomized.
- October 22, 2026 - Rgenta Therapeutics: The company reported FDA alignment on a Phase III trial design for oral MYB-targeting RGT-61159 in ACC, with trial initiation planned for the first quarter of 2027.
- October 19, 2026 - Servier: First patients were dosed in the pivotal Phase II EMBLEM-1 cohort evaluating B7-H4 ADC emiltatug ledadotin in aggressive ACC.
- July 16, 2026 - MD Anderson-sponsored study: The Phase II study of sacituzumab govitecan in recurrent or metastatic secretory-gland cancers posted an updated recruiting record covering ACC and non-ACC salivary histologies.
- July 6, 2026 - Janssen-sponsored YATAGARASU study: The trial record for apalutamide plus a GnRH agonist in androgen-receptor-positive salivary gland carcinoma was updated as active and no longer recruiting.
- June 25, 2026 - Avacta: The company announced FDA agreement on pivotal-trial elements for faridoxorubicin, including PFS as the sole primary endpoint for potential full approval.
- May 12, 2026 - Servier: The FDA granted Breakthrough Therapy designation to emiltatug ledadotin for locally advanced, recurrent or metastatic ACC with solid histology or high-grade transformation.
Strategic Key Takeaways
- ACC is now a registration-focused submarket. Multiple programs are moving toward pivotal studies with distinct targets and modalities.
- Histology alone is no longer sufficient. HER2, androgen receptor, NTRK, B7-H4, MYB and NOTCH testing divides the market into treatment-relevant groups.
- Central pathology is a commercial capability. Misclassification can distort eligibility, trial outcomes and reimbursement in a market with many rare subtypes.
- Randomized evidence remains valuable despite recruitment difficulty. Indolent ACC can make disease-control rates and historical PFS comparisons appear stronger than true drug effect.
- Oral agents could alter treatment logistics. A successful MYB-targeting tablet would shift part of advanced ACC care away from infusion-centered delivery.
- Japan provides a biomarker-led access precedent. The HER2-positive trastuzumab indication shows that a small molecular subset can support country-specific approval.
- Specialist referral networks determine trial speed. Sponsors with access to multinational rare-cancer centers can recruit faster and produce more consistent pathology and imaging review.
Why Purchase the Report?
- Visualize the composition of the salivary gland cancer treatment market segmentation by type, diagnosis, treatment, end user, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in salivary gland cancer treatment market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of salivary gland cancer treatment market- level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global salivary gland cancer treatment market report would provide an access to an approx. 55+market data table, 60+ figures and 268 pages.
